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Noroviruses (NoVs) of genogroup II, cluster 4 (GII.4), are the most common cause of outbreaks of acute
gastroenteritis worldwide. During the past 13 years, GII.4 NoVs caused four seasons of widespread activity
globally, each associated with the emergence of a new strain. In this report, we characterized the most recent
epidemic strain, GII.4-2006 Minerva, by comparing virus-like particle (VLP) antigenic relationships and
histo-blood group antigen (HBGA) binding profiles with strains isolated earlier. We also investigated the
seroprevalence and specificity of GII.4 antibody in the years prior to, during, and following the GII.4 pandemic
of 1995 and 1996 using a large collection of acute- and convalescent-phase serum pairs (n  298) collected from
34 outbreaks. In a surrogate neutralization assay, we measured the blockade of HBGA binding using a panel
of GII.4 VLPs representing strains isolated in 1987, 1997, 2002, and 2006 and a GII.3 VLP representing a strain
isolated in the mid-1990s. Serum titers required for 50% HBGA blockade were compared between populations.
In general, blockade of GII.4 VLP-HBGA binding was greater with convalescent-phase outbreak sera collected
near the time of origin of the VLP strain. Heterotypic genotypes did not contribute to herd immunity against
GII.4 NoVs based on their inability to block GII.4 VLP binding to HBGA. However, previous exposure to GII.4
NoV followed by infection by GII.3 NoV appeared to evoke an immune response to GII.4 NoV. These results
support the hypothesis that herd immunity is a driving force for GII.4 evolution in the U.S. population. The
data also suggest that complex patterns of cross-protection may exist across NoV genotypes in humans.
Human noroviruses (NoVs) of the family Caliciviridae are
the most common cause of acute gastroenteritis worldwide and
the leading cause of food-borne illnesses in the United States
(16, 51). Although generally causing a short-lived but acute
illness involving diarrhea and/or vomiting, more severe symp-
toms and fatalities have been reported among the elderly,
infants, and immunocompromised persons (6, 17, 41, 53). Out-
breaks in communal and institutional settings such as hospitals,
nursing homes, cruise ships, university dormitories, and mili-
tary barracks are frequently reported; furthermore, these in-
stitutions suffer the most significant economic damages during
NoV outbreaks due to direct health care costs, decontamina-
tion efforts, and indirect losses (35).
Currently, there are no vaccines or antiviral therapies ap-
proved for the treatment of NoV infections, and such efforts
have been significantly hampered by the lack of a simple cell
culture or small-animal model for human NoVs. All informa-
tion on host-pathogen interactions has come from human chal-
lenge studies and epidemiological investigations (1, 14, 16, 23,
27–29, 39, 40). As a result, the correlates of immune protection
are poorly understood. Recently, the use of recombinant virus-
like particles (VLPs) and replicon constructs has proven prom-
ising lines of research toward vaccine and antiviral develop-
ment (7, 12, 31, 32, 46). Additionally, computer-generated
structural modelings of NoV capsid proteins combined with
epidemiological and immunological investigations are proving
to be valuable new tools for the more specific and rational
design of vaccines and antivirals (30, 43).
NoVs have a 7.5- to 7.7-kb, single-stranded, positive-sense
RNA genome consisting of three open reading frames (ORFs)
packaged into a nonenveloped icosahedral capsid. Recombi-
nant expression of the ORF2 major capsid protein (VP1) in a
baculovirus or Venezuelan equine encephalitis (VEE) virus
expression vector has been successful for the production of
VLPs that are physically and antigenically similar to native
virus particles (2, 18). The surface-exposed P2 subdomain of
VP1 is the most hypervariable region of the genome and is
responsible for carbohydrate ligand binding (5, 8).
Histo-blood group antigen (HBGA) expression on the gut
mucosa has been shown to be correlated with susceptibility to
infection with the prototype Norwalk virus (23, 29). Several but
not all NoVs specifically bind to HBGAs, which likely function
in some capacity as a receptor for docking and entry into the
cell during infection (20–22, 24, 29). Recent epidemiological
studies indicate that there is an association between HBGA
expression and genetic susceptibility to NoV strains of geno-
group II, cluster 4 (GII.4), although the association is not as
clear as was shown previously with Norwalk virus (27, 47).
More than 25 genotypes of human NoVs have been de-
scribed (52), but GII.4 strains are the most prevalent globally.
Over the last two decades, NoV epidemic peaks associated
with GII.4 have been reported worldwide in 1996, 2002, 2004,
and 2006, and at least one novel GII.4 variant strain could be
* Corresponding author. Present address: University of Georgia Center
for Food Safety, 1109 Experiment St., Griffin, GA 30223. Phone: (770)
467-6094. Fax: (770) 229-3216. E-mail: jcannon@uga.edu.
 Published ahead of print on 18 March 2009.
5363
identified during each of these years (4, 11, 33, 38, 42). Epi-
demic seasons were followed by periods of moderate to low
NoV activity, where GII.4 strains cocirculated indiscriminately
along with NoVs of several other genotypes. During the GII.4
epidemic peaks of 1996 and 2002, the proportion of GII.4
strains causing outbreaks in the United States was greater than
50%, but between these years, the GII.4s were responsible for
just 10 to 29% of all NoV outbreaks (Centers for Disease
Control and Prevention [CDC], unpublished data). One year
after the GII.4 pandemic of 1995 and 1996, GII.3 NoV circu-
lation increased from about 4% in 1996 to about 25% in 1997
(38). After 2002, variant GII.4 strains emerged much more
quickly, causing epidemics every 1 to 2 years. This type of
epochal evolution has been described previously by our group
and others (9, 30, 43).
Recently, our group has proposed a mechanism for the per-
sistence of GII.4 in the human population based on the epi-
demic patterns observed for GII.4 strains during the past 20
years (30). Clear evidence of structural changes in the P2
region of the GII.4 capsid protein leading to alternative
HBGA receptor usage and immune evasion could be observed
for GII.4 strains isolated in 1987, 1997, 2002, 2004, and 2005.
HBGA binding with representative GII.4 VLPs supported the
structural models, and receptor blockade data provided by
hyperimmune mouse antisera unambiguously demonstrated
antigenic variation between GII.4 strains and phenotypic sup-
port for immune evasion. Furthermore, blockade patterns of
human sera from a GII.4 outbreak supported herd immunity as
the driving force for antigenic change (30).
Here, we expand upon our previous work by examining
receptor blockade patterns of human sera collected during
NoV outbreaks over a 21-year period from 1985 to 2006. Our
results support a general pattern of receptor blockade ex-
pected when herd immunity is the driving force of antigenic
change. Furthermore, we demonstrate that the receptor block-
ade assay has the specificity to discriminate minute differences
between heterotypic genogroups important for understanding
cross-protective immunity. Based upon these findings, we con-
clude that in addition to NoV strain surveillance, analyzing
human sera collected during routine outbreak surveillance may
be valuable for assisting in the choice of VLPs included in
vaccine candidates in an approach similar to that for influenza
virus.
MATERIALS AND METHODS
Serum and stool specimens. A total of 298 acute- and convalescent-phase
serum pairs from 34 outbreaks that occurred between 1985 and 2006 which had
been collected and archived at the National Calicivirus Laboratory at the CDC
(Atlanta, GA) were selected for this study. Acute-phase serum samples had been
collected between 0 and 7 days after the onset of illness, and convalescent-phase
serum samples had been taken 13 to 47 days after the acute-phase sample. For
outbreaks occurring from 1988 to 2006, corresponding stool specimens tested
positive for GII NoV and negative for GI NoV by reverse transcription (RT)-
PCR using primers targeting a small region of the capsid gene followed by
sequence analysis (26). Since stool samples were no longer available for 10 of the
11 outbreaks from 1985 to 1988, archival reports from the original CDC outbreak
investigation were studied for classifying outbreaks as being suspected of being
caused by NoV based on (i) fulfillment of Kaplan criteria (25) or (ii) positive test
for NoV by immune electron microscopy or enzyme immunoassay using conva-
lescent-phase sera from patients infected with Snow Mountain virus or Toronto
virus. In addition, outbreaks with serum samples demonstrating seroconversion
to Norwalk virus were excluded.
Stool sample processing. Viral RNA was extracted from 10% stool suspen-
sions (phosphate-buffered saline [PBS]) with the Ambion MagMax (Applied
Biosystems) kit and the KingFisher automated extractor (Thermofisher) and
tested for GII NoV by TaqMan real-time RT-PCR (48). Positive samples were
genotyped by amplifying region C (26) using a Qiagen (Valencia, CA) one-step
RT-PCR kit. Cycling conditions included an RT step for 1 h at 42°C and
activation of Taq polymerase at 95°C for 15 min followed by 35 cycles of 94°C,
50°C, and 72°C for 30 s each, followed by a final extension step for 7 min at 72°C.
Amplicons were sequenced using a Big Dye Terminator cycle sequencing kit,
BigDye X-Terminator purification kit, and the ABI (Foster City, CA) 3130
genetic analyzer.
VLPs. Complete ORF2 genes of NoV strains from outbreak stool specimens
collected in 1997, 2002, 2006, and 1999 and representing clusters GII.4-1997,
GII.4-2002, GII.4-2006, and GII.3-TV (Fig. 1), respectively, were amplified and
cloned into VEE virus replicons as previously reported (2, 30, 31). The GII.4-
1987 ORF2 gene was commercially synthesized by BioBasic and inserted into the
VEE virus replicon (30). VEE virus replicon particles were generated, and VLPs
were expressed in baby hamster kidney (BHK) cells, purified, and visualized by
negative-staining electron microscopy as described previously (2).
Serology. Between 1 and 35 serum pairs from each outbreak were tested for a
fourfold increase (seroconversion) in anti-GII.4 VLP immunoglobulin G (IgG)
titers between acute- and convalescent-phase sera by enzyme-linked immunosor-
bent assay (ELISA) as previously described (29). Briefly, 1 g/ml of VLPs diluted
in PBS was bound to 96-well plates for 4 h before plates were blocked overnight
in 5% Blotto. Twofold serial dilutions of acute- and convalescent-phase outbreak
patient sera were added to the plates, and human IgG specifically reacting with
the VLPs was detected using mouse anti-human IgG-alkaline phosphatase
(Sigma, St. Louis, MO) and para-nitrophenol phosphate (Sigma). Either GII.4-
1987 or GII.4-1997 VLPs were used, as previous results indicated that they are
antigenically very similar (30). NoV-specific IgG serum concentrations were
calculated by comparison to a standard curve of purified IgG and used to
calculate geometric mean titers (GMTs) of serum (dynamic range for IgG stan-
dard of 0.008 to 1 g/ml IgG). Comparisons between groups of convalescent-
phase serum specimens were done using Mann-Whitney analysis (http://faculty
.vassar.edu/lowry/VassarStats.html).
HBGA binding and blockade assays. HBGA binding studies were performed
under conditions identical to those for the HBGA blockade studies but without
the addition of human sera (see below). Briefly, 116 convalescent-phase sera
from patients from 28 outbreaks demonstrating seroconversion to GII.4 VLPs
were subjected to a surrogate neutralization assay to measure blockade antibody
titers as described previously (30, 31). Briefly, GII.4-1987, GII.4-1997, GII.4-
2002, GII.4-2006, and GII.3-TV VLPs (1 g/ml) were incubated with twofold
serial dilutions of sera at 37°C for 1 h. After washing plates with PBS–0.05%
Tween 20, the serum-VLP sample mixture was added to preblocked Neutravidin
plates (Pierce) that had been coated with 10 to 20 g biotinylated HBGA
(Glycotech) in 5% Blotto and incubated for 1.5 h at 37°C. Binding or VLP
blockade was detected using matched mouse anti-GII.4-VLP sera followed by
goat anti-mouse IgG-alkaline phosphatase (Sigma) and detection by para-nitro-
phenol phosphate (Sigma). H type 3 HBGA was used for GII.4-1987, GII.4-1997,
and GII.4-2006; Ley was used for GII.4-2002; and A type or H type 3 HBGA was
used for GII.3-TV based on the HBGA-VLP combination resulting in the high-
est optical density (OD) reading. For GII.3-TV experiments, the OD value for
the 100% binding controls were lower for A type than for H type 3 HBGA, but
blockade was linear and proportional, resulting in equivalent slopes.
By comparison to a control (VLP binding to HBGA in the absence of human
sera), 50% antibody blockade titers (BT50s) were determined with twofold
serum dilutions from 1:100 to 1:6,400. Geometric mean BT50s were calculated as
log-transformed reciprocal blockade antibody titers and are reported as back-
transformed titers. A BT50 was prescribed for a sample only when a linear
relationship between blockade serum titer and percent control binding could be
observed. To be considered acceptable, OD readings were between 0.1 and 3.0
above the background. Sera with a BT50 of less than 100 (a 1:100 dilution) or of
greater than 6,400 (a 1:6400 dilution) were given values of 100 and 6,400,
respectively. BT50 values were compared between groups of serum samples
using Mann-Whitney analysis (http://faculty.vassar.edu/lowry/VassarStats.html).
Blockade experiments using antisera collected from mice immunized with GII.4-
1997 or GII.3-TV VLPs were done as previously reported (30).
Homology model of GII.3. A homology model of the GII.3 capsid P domain
was generated using the X-ray crystal structure of the P domain of GII.4 virus
VA387 in complex with B trisaccharide (5) (Protein Data Bank accession num-
ber 2OBT [http://www.rcsb.org/pdb/home/home.do]) as a template. Briefly, an
alignment of the GII.4 and GII.3 P-domain regions was generated and demon-
strated sequence identity greater than 60%, indicating that GII.4 was an appro-
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priate template for generating the GII.3 homology model. The GII.3 homology
model was then generated using the program Modeler, version 8.2, using the
automodel class (10, 36). The Protein Data Bank file generated for the GII.3 P
domain was visualized on the molecular modeling tool MacPyMol (DeLano
Scientific).
RESULTS
Characteristics of outbreaks from 1985 to 2006 and repre-
sentative VLPs. Since first being described in 1987, at least
seven GII.4 NoV variants have been circulating within the U.S.
population. Figure 1 indicates epidemic peaks of NoV activity
in the United States from 1985 to 2006, centered on the first
documented GII.4 pandemic (1995 to 1996). Specific time pe-
riods, dubbed here “prepandemic,” “pandemic,” “lull,” and
“Minerva,” were chosen to explore serological relationships of
homotypic and heterotypic patient outbreak sera with VLPs
representative of chronological GII.4 NoVs. Because the NoV
pandemic of the mid-1990s was followed by a sharp rise in
GII.3 activity in the United States and a subsequent period of
very little GII.4 or GII.3 activity, serological relationships
among GII.4 and GII.3 outbreak sera and their representative
VLPs were investigated. We have previously reported the char-
acteristics of VLPs representing GII.4-1987, GII.4-1997, and
GII.4-2002 (30). For this study, we designed two additional
novel VLPs. The first represents the epidemic GII.4-2006
Minerva strain that emerged in 2006, reaching epidemic propor-
tions in the United States and Europe. The second, GII.3-TV,
represents the GII.3-Toronto virus that circulated in the
United States in 1999.
Variation within the P2 subdomain resulting in differential
patterns of HBGA binding, and, thus, host susceptibility, has
been suggested to be one possible mechanism for GII.4 NoV
persistence (30). Figure 2 shows the HBGA binding patterns of
the VLPs used in this study. As reported previously, GII.4-
1987 bound to H type 3; GII.4-1997 bound to H type 3, Ley,
Leb, and A and B trisaccharides; and GII.4-2002 bound to H
type 3 and Ley (30). The HBGA binding pattern for GII.4-2006
VLP is nearly identical to that of GII.4-1997 binding to H type
3, Ley, Leb, and A and B trisaccharides. GII.3-TV VLPs bound
to H type 3 and A trimer.
Serological relatedness among outbreak sera from 1985 to
2006. To study the antigenic relationship between the GII
NoVs circulating between 1985 and 2006, we analyzed anti-
GII.4 VLP IgG from serum pairs collected during 34 GII NoV
outbreaks (Table 1). In all, 140 (47%) of the 298 GII outbreak
serum pairs had at least a fourfold increase in levels of reactive
IgG to GII.4-1987 or GII.4-1997 between acute- and convales-
cent-phase serum collection (seroconverted), including at least
one serum pair from 32 of the 34 outbreaks. Within the four
chronological periods, 56 (42%), 51 (49%), 27 (51%), and 6
(100%) serum pairs seroconverted to GII.4 VLPs during the
prepandemic, pandemic, lull, and Minerva periods, respectively.
To assess serological relationships among homotypic and hetero-
typic outbreak sera, the data were further stratified by genotype.
Figure 3 indicates the GMTs (g/ml) of IgG reactive with GII.4-
1987 or GII.4-1997 VLPs in acute- and convalescent-phase sera
from patients seroconverting to GII.4 VLP.
The GII.4 sera from the pandemic period had the greatest
geometric mean convalescent IgG titers (mean GMT of 365
g/ml) (Fig. 3A). Compared to this group, GMTs for conva-
lescent-phase sera did not differ significantly between the GII.4
outbreaks during the prepandemic, lull, or Minerva periods
(P  0.91) (mean GMTs of 331, 306, and 297 g/ml, respec-
tively). Consonant with previous reports by our group (30), this
suggests antigenic similarities among GII.4 NoVs circulating
from 1985 to 2006. In addition, cross-reactivity was observed
FIG. 1. Timeline from 1985 to 2006 indicating the classifications for the populations from which outbreak serum specimens were collected and
the VLPs used in this study.
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for the GII.4 VLPs and sera from the GII-unspecified out-
breaks from the prepandemic period (mean GMT of 219 g/
ml) (Fig. 3B). In contrast, convalescent-phase sera from non-
GII.4 outbreaks from the lull period had a mean GMT equal to
165 g/ml, which was significantly lower than that of the GII.4
sera from the pandemic period (P  0.02), and prepandemic
and lull-period GII.3 sera were not very cross-reactive with
GII.4 VLPs (mean GMTs of 46 g/ml and 65 g/ml, respec-
tively), demonstrating antigenic dissimilarities between hetero-
typic genotypes. Interestingly, though, GMTs for GII.3 out-
break sera from the pandemic period were high (mean GMT
of 282 g/ml) and did not differ from that of the pandemic
GII.4 sera (P  0.28) (Fig. 3C), indicating antigenic similarity
or evidence of an immunological memory response from a
previous GII.4 infection.
Blockade of GII.4 VLP binding to HBGA by homotypic and
GII.4 outbreak sera. Regardless of the GII outbreak strain,
many of the serum pairs tested by ELISA demonstrated cross-
reactivity to GII.4 VLPs. To further determine the specificity
of serum antibodies, convalescent-phase sera from the 116
serum pairs that seroconverted to GII.4 VLPs were further
tested for their ability to block GII.4 VLP binding to HBGAs.
First, we analyzed blockade by homotypic antisera. The GII.4-
2006 VLP was cloned from a stool specimen collected from a
GII.4 Minerva outbreak in 2006. The GII.4-2006 outbreak sera
discussed above were collected from this same outbreak.
Acute-phase sera collected from this outbreak did not block
the binding of GII.4-2006 to HBGA at any concentration
tested, but binding could be efficiently blocked by the homo-
typic convalescent-phase sera from all six patients involved in
FIG. 2. HBGA binding of GII.4-1987, GII.4-1997, GII.4-2002 (30), GII.4-2006, and GII.3-TV VLPs. Boxes indicated averages, and bars
indicate maximum OD values at 405 nm.
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the 2006 outbreak, as the geometric mean BT50 of VLP-
HBGA binding was 2,016 (Fig. 4).
To expand upon the HBGA blockade data reported above
and to investigate if blockade patterns indicative of herd im-
munity could be revealed using outbreak sera from patients
infected with GII NoVs, 65 convalescent-phase serum speci-
mens collected from 15 outbreaks ranging from 1988 to 2000
were tested in the surrogate neutralization assay, in addition to
the 2006 outbreak noted above. Sera from outbreaks that were
confirmed to be caused by GII.4 NoV (45 specimens from
eight outbreaks) were examined for the ability to block GII.4
VLP binding to HBGA (Fig. 5). In the prepandemic period,
geometric mean BT50 values were similar for GII.4-1987
(BT50 of 680) and GII.4-1997 (BT50 of 737) VLPs (P  0.83),
and these values were significantly greater than the geometric
mean BT50 value for GII.4-2002 VLP (BT50 of 301) (P  0.03
for 1987 versus 2002; P  0.02 for 1997 versus 2002). Similarly,
in the pandemic period, the geometric mean BT50 values for
GII.4-1987 (BT50 of 1,467) and GII.4-1997 (BT50 of 2,363)
were similar (P  0.14) but were significantly greater than that
of GII.4-2002 (BT50 of 336) (P  0.01 for 1987 versus 2002;
P  0.01 for 1997 versus 2002). Alternatively, during the lull
period, geometric mean BT50 values did not differ among the
three VLPs (BT50 values of 1,213, 1,716, and 1,056 for GII.4-
1987, GII.4-1997, and GII.4-2002, respectively) (P  0.51 for
1987 versus 1997; P  1 for 1987 versus 2002; P  0.47 for 1997
versus 2002). Together, the higher BT50 values over time dem-
onstrated with the GII.4-2002 VLP using GII.4 outbreak sera
indicate that the circulation of strains similar to GII.4-2002
appeared only in the few years leading up to the GII.4-2002
epidemic that emerged in the United States in 2002. Geomet-
ric mean BT50 titers for the six convalescent-phase serum
samples isolated from the 2006 GII.4-Minerva outbreak were
all high and did not differ significantly between the different
GII.4 VLPs, GII.4-1987 (BT50 of 800), GII.4-1997 (BT50 of
1,131), and GII.4-2002 (BT50 of 1,796) VLPs (P  0.58 for
1987 versus 1997; P  0.21 for 1987 versus 2002; P  0.42 for
FIG. 3. Geometric mean IgG titers in acute- and convalescent-
phase sera from outbreak patients seroconverting to GII.4-1997 or
GII.4-1987 VLPs. Data are stratified by period and by genotype of the
outbreak, including only GII.4 outbreaks (A), GII-unspecified (pre-
1988 sera) and non-GII.4 outbreaks (non-GII.4 represents sera from
outbreaks caused by GII.1, GII.2, GII.10, and GII.14 NoVs) (B), and
only GII.3 outbreaks (C). Boxes represent maximum, mean, and min-
imum values for geometric mean IgG titers in each category. * indi-
cates a significant difference in mean IgG titers between acute- and
convalescent (Conv)-phase sera, and ˆ indicates a significant difference
between the mean convalescent IgG titers compared to those of GII.4
outbreaks of the pandemic period.
FIG. 4. Blockade of GII.4-2006 VLP by homotypic outbreak sera.
Acute-phase (n  6) and convalescent-phase (n  6) serum pairs
collected during the GII.4-2006 outbreak from which the GII.4-2006
VLP was cloned were assayed for the ability to block homotypic VLP
interactions with H type 3. Error bars indicate the standard errors. The
dashed line indicates the corresponding BT50 values on the x axis.
FIG. 5. Blockade of GII.4 VLP binding to HBGA by convalescent-
phase GII.4 outbreak sera collected during 1988 to 2006. Geometric
mean BT50 values for each VLP represent the geometric means of
individual BT50 values for each serum sample within the indicated
time period. Error bars indicate the standard errors. * indicates sig-
nificant differences between GII.4-1987, GII.4-1997, or GII.4-2002
VLPs within each period.
5368 CANNON ET AL. J. VIROL.
1997 versus 2002) (Fig. 5), suggesting an immunological mem-
ory response to earlier GII.4 strains stimulated upon infection
with GII.4-Minerva.
Blockade of GII.4 VLP binding to HBGA by heterotypic
outbreak sera. To investigate the influence of heterotypic GII
NoVs on the GII.4-VLP HBGA blockade, we examined the
heterotypic sera from each period, individually. During the
prepandemic period, the geometric mean GII.4-specific IgG
titer was high for the 37 serum pairs collected from patients
from GII-unspecified outbreaks, but the geometric mean BT50
was very low for all VLPs tested (mean BT50 values of 364 for
GII.4-1987, 604 for GII.4-1997, and 291 for GII.4-2002) (Fig.
6A). Similarly, convalescent-phase sera from GII.1, GII.2,
GII.10, and GII.14 outbreaks in the lull period did not block
GII.4 VLP binding, as geometric mean BT50 values were 381,
442, and 244 for GII.4-1987, GII.4-1997, and GII.4-2002, re-
spectively, demonstrating antigenic dissimilarities between
GII.4 and the heterotypic genotypes (Fig. 6B).
Convalescent-phase sera from GII.3 outbreaks in the pan-
demic period were less capable of blocking GII.4-1987 and
GII.4-2002 VLP binding to HBGA (geometric mean BT50
values of 566 for GII.4-1987, 651 for GII.4-1997, and 519 for
GII.4-2002) than for blocking the binding of GII.3-TV VLP
(geometric mean BT50 of 2,691) (P  0.01 for 1987 versus TV;
P  0.05 for 1997 versus TV; P  0.01 for 2002 versus TV)
(Fig. 6C), and GII.4 outbreak sera from the pandemic period
were even less capable of blocking GII.3-TV binding to HBGA
(geometric mean BT50 of 453; P  0.01) (Fig. 6D). However,
the geometric mean BT50 for GII.3 pandemic-period serum
blockade of GII.4-1997 (mean BT50 of 1,131) did not signifi-
cantly differ from the geometric mean BT50 (mean BT50 of
2,363) for the GII.4 pandemic-period serum blockade of GII.4-
1997 VLPs (P  0.13). This indicates either antigenic similar-
ities between GII.4 and GII.3 or a memory response from a
previous GII.4 infection elicited by the current GII.3 infection.
Using mouse hyperimmune antisera, we removed the possible
influence of previous NoV exposure and examined homotypic
and heterotypic cross-reactivity and blockade of GII.4 and
GII.3 VLP binding to HBGA. Figure 7 clearly indicates that
heterotypic blockade does not occur between GII.4-1997 and
GII.3-TV. GII.3-TV antisera effectively blocked homotypic
VLP-HBGA interactions but were unable to block the GII.4-
1997 interaction with HBGA. Likewise, antisera to GII.4-1997
VLPs blocked homotypic VLP but not GII.3-TV VLP interac-
tions with HBGA.
DISCUSSION
During the winter season of 1995 to 1996 (pandemic period),
an acute increase in GII.4 NoV activity was reported world-
wide (38, 49). This was followed by a 5-year period of relative
quiescence (lull period) for GII.4s until an antigenic variant
GII.4 strain (Farmington Hills) emerged in 2002, causing the
second reported NoV causing a global spike in GII.4 activity
(33, 50). Since this time, antigenic variants of GII.4 NoVs have
emerged every 1 to 2 years (30). Our group recently proposed
antigenic drift as being one mechanism for GII.4 NoV evolu-
tion and described its similarities to influenza A virus evolu-
tion, for which a variant H3N2 virus emerges every 3 years on
average (30, 44). Antigenic variation between current and con-
temporary GII.4 strains was demonstrated with hyperimmune
mouse antisera and with convalescent-phase sera from a 1988
GII.4 NoV outbreak (30). Here we examined a larger panel
GII NoV outbreak sera from 1985 to 2006 to estimate herd
immunity to GII.4 NoV in the U.S. population over time,
focusing on periods between the 1995 and 1996 pandemic and
the emergence of the next GII.4 antigenic variant in 2002, the
period prior to the first GII.4 strain to be sequenced, and
during domination of a contemporary GII.4 (Minerva) strain
in 2006.
The GII.4-MD145 strain detected in a 1987 NoV outbreak
was the first characterized GII.4 strain (17), and to date, no
prior GII.4 sequences have been reported. The GII outbreak
sera collected during 1985 to 1987 required high concentra-
tions of convalescent-phase sera to effectively block HBGA
binding of GII.4-1987, GII.4-1997, and GII.4-2002 VLPs. This
finding as well as the low numbers of serum specimens that
seroconverted are evidence for either low circulation levels of
GII.4 strains prior to 1987 or circulation of GII.4 antigenic
variants having some cross-reactivity with recognized GII.4s
but being unable to prevent GII.4 VLP binding to HBGA in
the surrogate neutralization assay.
The GII.4 sera collected during the pandemic period showed
a blockade pattern expected for a population recently exposed
to GII.4-1997 but unexposed to the GII.4-2002 virus. All sera
blocked the binding of GII.4-1997 VLPs (and the antigenically
similar GII.4-1987 VLPs) to HBGA but were less capable of
blocking binding of GII.4-2002 VLPs. In the years leading up
to the next GII.4 epidemic with widespread activity in 2002,
GII.4 strains circulated at relatively low levels, causing only
about half the total number of NoV outbreaks annually (hence,
the “lull-period” nomenclature) (34). By 2000 to 2001, GII.4
NoVs were detected in only 16% of outbreaks but increased to
61% during the following winter season (3). About 50% of our
lull-period serum specimens were from GII.4 outbreaks, and
the others were from other GII genotypes. Sera from non-
GII.4 outbreaks during the lull period had low anti-GII.4 IgG
titers and were unable to block GII.4 VLP binding to HBGA,
indicating that these viruses likely share some common capsid
epitopes with GII.4 VLPs but likely lack specific neutralizing
epitopes. Therefore, infection by the heterotypic GII strains
examined in this study (GII.1, GII.2, GII.10, and GII.14) would
not likely be protective against GII.4 infection and likely did
not contribute to herd immunity against GII.4 NoVs.
The lull period which we describe for GII.4 NoVs is also very
similar to a period in the early 1980s when there was a stag-
nation in influenza A virus (H3N2) antigenic diversity for 8
years before a new antigenic variant emerged in 1987 (44). This
period where mutants are unable to overcome a fitness barrier
has been described as a “strain lock,” which may occur in both
naturally infected and vaccinated populations between periods
of antigenic drift (13). Low-level circulation of GII.4 NoVs
between 1997 and 2001, and the inability of non-GII.4 strains
to cross-block HBGA binding of GII.4 VLPs, suggests a con-
tribution to the suppression of GII.4-1997 epidemics by immu-
nological memory.
Interestingly, sera from the GII.4 outbreak from the lull
period blocked the binding of GII.4-1987, GII.4-1997, and
GII.4-2002 VLPs, even though sera were collected before
GII.4-Farmington Hills strains dominated globally. New vari-
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ants of influenza A virus begin to circulate 2 years prior to the
period for which they were the dominant cluster (44). Several
minor GII.4 strains in circulation during the lull period have
genetic similarities to GII.4-2002 (CDC, unpublished) and may
be antigenically similar as well. P2 region sequencing of the
lull-period GII.4 strains revealed 100% amino acid identity
with GII.4-1997, indicating that a blockade of GII.4-2002 by
the patient sera was likely not the result of the current GII.4
infection but possibly due to a memory response to a previous
exposure to a GII.4-2002-like strain. However, if immunity to
GII.4-2002-like strains began prior to the years of its domina-
tion, the proportion must have still been too low to generate
sufficient herd immunity to prevent the 2002 epidemic. It is
therefore likely that the persons infected with GII.4 during the
lull period in this study are not representative of the “herd”
population.
Alternatively, we know that two strains of GII.4-Farmington
Hills cocirculated in 2002. The representative VLPs, GII.4-
2002 and GII.4-2002a, differ in the P domain by only 2 amino
acids but are antigenically very distinct (30). While the propor-
tion of each strain in circulation in the United States during
this time is not known, it is possible that GII.4-2002-like strains
circulated in the late 1990s but that GII.4-2002a-like strains (or
other antigenically distinct GII.4-Farmington Hills strains)
were primarily responsible for the U.S. epidemic.
During the pandemic period, 69% of the NoV outbreaks
were caused by GII.4 viruses (38). The following year, the
number of GII.4 outbreaks dropped to 31%, but the number of
GII.3 outbreaks increased from about 4% in 1995 to 1996 to
about 25% in 1996 to 1997 (38). We and others (37) have
shown that convalescent-phase GII.3 outbreak sera are rela-
tively cross-reactive with GII.4 VLPs. However, the pandemic-
period GII.3 sera used in the current study had very high levels
of anti-GII.4 IgG that also effectively blocked GII.4-1997 VLP
binding to HBGAs to about the same degree as GII.4 pan-
demic-period sera blocked GII.4-1997. GII.4 pandemic sera
did not, however, block HBGA binding of the GII.3-TV VLPs,
suggesting that the sharp rise in the number of GII.4 outbreaks
in 1996 could not prevent the rise in numbers of GII.3 outbreaks
the following year. Because no cross-blockade of HBGA binding
could be observed between GII.4-1997 and GII.3-TV with hy-
perimmune mouse antisera, these data suggest that patients
infected with GII.3 NoV during the pandemic period were
previously infected with a GII.4 NoV and that an immunolog-
ical memory response was evoked for GII.4 following the GII.3
infection. Not only could this have helped in generating suffi-
cient herd immunity to quell the pandemic, but it also suggests
that GII.3 and GII.4 NoVs share some structural similarities.
Comparison of the structural models of the dimer of the
GII.4 and GII.3 P domains demonstrated that the two P do-
mains share significant identity, which could allow cross-reac-
tivity of GII.4 antibodies with the GII.3 VLPs (Fig. 8a). How-
ever, the major difference between these two P domains is that
the P2 subdomain of the GII.3 strain probably contains a large
loop that extends away from the surface and away from the
region that contains the reported receptor binding domain
(RBD) in the GII.4 P domain (Fig. 8b). Further comparison of
the structural models of the GII.3 and GII.4 P domains re-
vealed nearly identical residues in interaction site 1 and similar
residues in interaction site 2, two regions which have been
shown to be important for interacting with the HBGAs to
which the GII.4 virus binds (5). This observation suggests that
a similar RBD exists on the GII.3 surface, suggesting that the
GII.3 viruses may use the same receptor binding site as GII.4-
1997 (Fig. 8b). However, in site 2 of GII.3, there is a deletion,
exemplifying that although there are many similarities between
FIG. 6. Blockade of GII.4 or GII.3 VLP binding to HBGA by convalescent GII-unspecified outbreaks from the prepandemic period (A), non-GII.4
sera from the lull period (B), GII.3 sera from the pandemic period (C), and GII.4 sera from the pandemic period (D). The dashed line indicates the
corresponding BT50 values on the x axis. Error bars indicate the standard errors.
FIG. 7. Murine antiserum blockade of GII.4-1997 and GII.3 binding to HBGA. Antisera collected from mice immunized with GII.4-1997 (n 
3) or GII.3-TV (n  3) were assayed for the ability to block homotypic VLP (solid symbols) or heterotypic VLP (open symbols) interactions with
H type 3. The dashed line indicates the corresponding BT50 values on the x axis.
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GII.4-1997 and GII.3-TV, there are also several differences
that could make them antigenically distinct.
We also describe GII.4-2006 HBGA binding and found it to
be very similar to that of GII.4-1997 although appearing to be
somewhat weaker in affinity. Previously, we demonstrated two
contemporary GII.4 strains (GII.4-2004 and GII.4-2005) that
did not bind to any of the HBGAs tested, but the reversion to
HBGA binding further demonstrates the plasticity of the virus
RBD. The sera from the 2006 GII.4 outbreak blocked HBGA
binding for all GII.4 VLPs tested, suggesting a memory re-
sponse to chronological GII.4 strains elicited by infection with
an extant GII.4 strain. Alternatively, epitopes of chronological
strains may be recycled in extant strains, allowing cross-reac-
tivity. Mouse antisera raised against GII.4-2004 and GII.4-2005
strains block both GII.4-2002a and GII.4-1987 VLPs (30). In
both scenarios, infection by the emergent strain will likely
confer protection from strains of recent years and may provide
some level of protection to strains of previous decades.
This study has many limitations because it was designed
retrospectively, and the specimens used in our analysis were
drawn from a subset of the population that may not be repre-
sentative of the U.S. population. Because NoV outbreak sur-
FIG. 8. Structural models of the GII.3 and GII.4 P-domain dimers. (a) Structural similarities between the GII.3 and GII.4 P-domain dimers
suggest that similar structural features would appear on the capsid structure of each VLP or virus. The GII.3 P-domain dimer model is shown in
various rotations, and sites that are identical between GII.3 and GII.4 P dimers are shown in black. Blue, chain A; purple, chain B; yellow, site
1 of the putative RBD; orange, site 2 of the putative RBD. (b) Direct comparison of the GII.4 P-domain dimer with the GII.3 P-domain dimer
model indicates that a unique extended loop occurs on the GII.3 structure distal to the dimer interface, which would likely provide a unique target
for antibody neutralization specific to the GII.3 virus/VLP.
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veillance is passive, the samples received by the CDC may be
biased toward large-scale outbreaks or outbreaks with more
severe clinical symptoms such as those involving nursing home
residents. Although serological responses to NoV infection by
elderly patients were robust and did not appear to differ from
those of younger persons, the sample size was not sufficient for
statistical comparisons. Therefore, the large proportion of el-
derly patients sampled during the pandemic period may have
biased our results. Also, by excluding sera from persons that
did not serocovert to GII.4 NoV, we do introduce bias in our
interpretation of the data. Figure 3 does not model population-
level cross-reactive seroresponses to GII.4 NoV upon infection
with GII NoV. However, by combining the data from Fig. 3
with the proportion of seroconvertants for each outbreak, to-
gether with surveillance data estimating the number of persons
exposed to GII.4 NoV during the periods surrounding the
pandemic period, we are better able to generalize data for the
U.S. population. Additionally, we do not have exposure history
information for the outbreak patients in our study, and thus,
we do not know how much of the measured antibody reactivity
is a reflection of a memory immune response from previous
NoV infections. The seroconvertants included in this study had
generally low levels of GII.4 NoV cross-reactive antibodies in
their acute-phase sera, and none significantly blocked GII.4
VLPs when a subset was tested. This provides evidence for the
apparent lack of a recent GII.4 NoV infection but does not
exclude any possible contributions from a memory response.
In addition, only serum samples were available for our anal-
yses, as no salivary or mucosal specimens were available, and
fecal immunoglobulins are not sufficient for the detection limit
of the surrogate neutralization assay (31). While an early sal-
ivary IgA response is correlated with protection from Norwalk
virus but not Snow Mountain virus (28, 29), the contribution of
serum IgG to the immune response against NoV infection
remains unclear. However, at lower levels, mucosal antibodies
are produced after NoV vaccination and natural infection. In
addition, IgG in serum can transfer to the gut via transudation,
and IgG from the gut and spleen is capable of blocking 100%
of VLP binding to HBGA (31).
The application of the HBGA surrogate neutralization assay
used in this study is comparable to the hemagglutinin inhibi-
tion (HI) assay for human influenza virus in that both measure
blockade virus or VLP binding to a receptor. While an HI titer
of 1:40 (40) is generally accepted as the titer needed for a 50%
reduction in susceptibility to infection, all BT50 values ex-
ceeded 40 using the HBGA assay for NoV. Stephenson et al.
(45) previously reported that while virus neutralization assays
may be more sensitive and perhaps more strain specific than
HI assays, no correlates of 50% protection have been estab-
lished. The surrogate neutralization assay for human NoV may
also overestimate true neutralization, as regions of the capsid
distant from the receptor binding region may also be important
for infection.
Currently, there is no vaccine or antiviral therapy for con-
trolling NoVs. Efforts have been significantly hampered by the
lack of an in vitro culture system or small-animal infectivity
model. However, with our current knowledge of NoV evolu-
tion, such a vaccine will likely have to be updated every 1 to 2
years in a fashion similar to that of the influenza virus vaccine
in order to protect against emergent strains (30).
This study has provided us with serological data to support
long-term herd immunity against GII.4 NoVs. Using a surro-
gate neutralization assay, we were able to uncover minute
antigenic differences between NoVs that cannot easily be dis-
tinguished by phylogenetic analysis or basic serological assays
(ELISA). This study suggests a need for continued serological
surveillance for human NoVs. Surrogate neutralization data
along with outbreak sera can help us identify antigenically
distinct, emerging GII.4 strains that may begin circulation to-
ward the end of an epidemic, as neutralization assays help
identify influenza virus vaccine candidates. Well-designed pro-
spective studies including serological and HBGA blockade
studies will become increasingly important as VLP vaccines for
human NoVs become a reality.
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